Why the study?
Is the expression of hSR-B1/CLA-1 on platelets altered in patients with atherosclerotic disease compared to controls?
Population
Patients with atherosclerotic disease and control subjects (human platelets and megakaryocytes)
Design
Case-control
Authors
Loading...
Reduced platelet hSR-B1/CLA-1 associates with atherosclerosis and aggregation; leaves open biomarker or target utility pending validation.
Is the expression of hSR-B1/CLA-1 on platelets altered in patients with atherosclerotic disease compared to controls?
Reduced expression of the HDL receptor hSR-B1/CLA-1 on platelets is associated with atherosclerotic disease and increased platelet aggregation, suggesting its potential as a clinical marker.
Imachi et al. (2003) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: